在肺部沙丘病症中治疗粒状炎症的治疗方法
1Pulmonary and Critical Care Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Journal of clinical medicine
|February 10, 2024
概括
管理肺性沙尔科毒症需要平衡治疗风险与肺部保护. 对这种粒状肺病的治疗决定应根据症状严重程度和纤维化潜力进行个性化.
科学领域:
- 肺部医学 肺部医学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 肺癌型硬化症是一种多系统颗粒状疾病,临床过程具有变化.
- 管理包括平衡治疗疗效与潜在副作用以及患者的生活质量.
- 在开始治疗之前,高自发解脱率需要仔细考虑.
研究的目的:
- 概述治疗肺癌沙尔科毒症的原则.
- 讨论皮质类固醇和新兴皮质类固醇节约剂的作用.
- 强调个性化治疗策略的重要性.
主要方法:
- 目前关于肺部型硬化症管理的文献综述.
- 对各种治疗选择的治疗指南和证据的分析.
- 考虑疾病特征,患者因素和治疗结果.
主要成果:
- 肺性沙丘症治疗适用于显著症状,肺功能下降或成像检测结果预测纤维化.
- 皮质类固醇仍然是控制颗粒状炎症的基石.
- 皮质类固醇节约剂对于耐火病例,类固醇不耐受性或剂量限制性毒性有价值.
结论:
- 由于疾病的异质性,个性化治疗对于肺性沙尔科毒症至关重要.
- 治疗决策必须权衡控制颗粒状炎症的益处与治疗的风险.
- 优化肺部的保存和生活质量是治疗肺部类固醇症的主要目标.
更多相关视频
相关概念视频
Pulmonary Tuberculosis II
237
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
237
Pulmonary Tuberculosis V
180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
COPD: Management Using Bronchodilators and Corticosteroids
206
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
206
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164
Cystic Fibrosis: Management
164
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
164


